Targeted Sequencing and Resequencing Market Size & Growth Forecast 2026–2035, By Segments (Technology, End-use, Type, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Targeted Sequencing and Resequencing Market size was assessed at USD 8.66 Billion in 2025 and is poised to grow at a 21.9% CAGR between 2026 and 2035, exceeding USD 62.74 Billion by 2035. The industry revenue for 2026 is estimated at USD 10.38 billion.
Get more details on this report
Request Free Sample ReportTargeted Sequencing and Resequencing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 52.69% share in 2025, supported by established genomics infrastructure, widespread clinical adoption, and strong demand from pharmaceutical, biotechnology, and academic organizations.
- Asia Pacific is projected to expand at a 24.09% CAGR as precision medicine initiatives, laboratory capacity expansion, and broader sequencing adoption increase demand across healthcare and research settings.
Segment Momentum
- Sequencing held a 68.68% market share in 2025 because it serves as the primary technology for generating genomic data, supporting baseline genetic profiling, mutation detection, and first-pass analyses across targeted applications.
- Hospitals & clinics are expanding fastest as targeted genomic testing becomes part of routine patient care, with demand driven by actionable results, shorter reporting times, and stronger integration into diagnosis and treatment decisions.
Market Expansion Drivers
- Expanding precision oncology driving targeted genetic testing adoption in clinical workflows.
- Increasing R&D in genomics accelerating biomarker discovery and disease research applications.
- Declining sequencing costs improving accessibility of targeted NGS platforms in diagnostics.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Key companies in the targeted sequencing and resequencing market include Illumina, Inc. (United States), Agilent Technologies, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Oxford Nanopore Technologies plc (United Kingdom), Pacific Biosciences of California, Inc. (United States), QIAGEN N.V. (Germany), BGI Genomics Co., Ltd. (China), PerkinElmer Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As precision oncology becomes more embedded in routine cancer care, clinicians are relying on targeted genetic testing to match patients with therapy options, identify actionable mutations, and guide treatment selection with greater confidence. This transition is driving demand for the targeted sequencing and resequencing market because targeted panels fit clinical workflows more effectively than broader sequencing approaches when fast turnaround, focused interpretation, and reimbursement alignment matter most. Hospital laboratories and reference labs are expanding use of targeted NGS assays in solid tumor and hematologic testing pathways, which increases recurring test volumes and supports market expansion through more standardized integration of sequencing into diagnosis and treatment decision-making.
Increasing R&D in genomics accelerating biomarker discovery and disease research applications
Rising genomics research activity is increasing the use of targeted sequencing tools in studies focused on variant validation, pathway analysis, and biomarker identification, especially where researchers need high-depth coverage of defined genomic regions rather than whole-genome breadth. In the targeted sequencing and resequencing market, this strengthens market development by aligning platform adoption with translational research priorities, including companion diagnostics development, disease stratification, and longitudinal mutation tracking. Research institutions, biopharma companies, and clinical research programs are channeling investment toward applications where targeted resequencing produces more actionable datasets at the study level, reinforcing market demand through steady assay consumption and method expansion.
Declining sequencing costs improving accessibility of targeted NGS platforms in diagnostics
Lower sequencing costs are making targeted NGS more practical for a wider range of diagnostic laboratories, particularly those balancing budget constraints with the need to improve molecular testing capabilities. In the targeted sequencing and resequencing market, cost reduction influences market adoption by narrowing the barrier between conventional single-gene tests and multiplexed targeted panels, allowing labs to justify broader implementation based on workflow efficiency and per-sample value. This is increasing market penetration as smaller hospitals, regional labs, and emerging diagnostic providers gain access to targeted platforms that can deliver clinically relevant genomic information without the infrastructure burden associated with more expansive sequencing strategies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding precision oncology driving targeted genetic testing adoption in clinical workflows | 2.80% | High | North America, Europe | High | Near Term |
| Increasing R&D in genomics accelerating biomarker discovery and disease research applications | 2.40% | High | North America, Asia Pacific | High | Mid Term |
| Declining sequencing costs improving accessibility of targeted NGS platforms in diagnostics | 2.10% | Moderate | Global | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading position in 2025, accounting for a 52.69% share of the targeted sequencing and resequencing market. This leadership is supported by the region’s established genomics research infrastructure, broad use of sequencing in clinical and translational settings, and consistent demand from pharmaceutical, biotechnology, and academic users. In practice, this creates a high-throughput environment where sequencing platforms, assay workflows, and bioinformatics capabilities are already embedded into routine research and diagnostic activity, reinforcing purchasing volumes and repeat use across end users.
Asia Pacific is projected to expand at a 24.09% CAGR over the forecast period, reflecting faster adoption of the targeted sequencing and resequencing market across research and healthcare settings. Growth is being impelled by the increasing integration of sequencing into disease profiling, precision medicine initiatives, and expanding genomics capacity across laboratories and clinical institutions. As more facilities build local testing capability and move from pilot-stage adoption to broader operational use, demand strengthens for sequencing panels, supporting workflows, and associated analytical services across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany emphasizes validated targeted sequencing workflows for molecular diagnostics and translational research. German laboratories increasingly adopt standardized sequencing solutions that improve reproducibility while meeting stringent clinical and regulatory expectations.
France 🇫🇷
Translational Research SupportFrance advances targeted sequencing through collaborative research programs linking academic institutions, hospitals, and biotechnology companies. French laboratories focus on generating clinically relevant genomic insights that improve disease characterization and therapeutic decision-making.
Italy 🇮🇹
Molecular Testing AdoptionItaly continues expanding targeted sequencing within hospital laboratories and specialized diagnostic centers. Italian healthcare providers prioritize cost-effective genomic workflows that strengthen molecular testing capabilities across oncology and inherited disease applications.
Japan 🇯🇵
Advanced Diagnostic IntegrationJapan integrates targeted sequencing into cancer care, rare disease research, and precision diagnostics. Japanese healthcare organizations prioritize reliable sequencing technologies that enhance diagnostic accuracy and enable efficient genomic data analysis.
South Korea 🇰🇷
Genomic Innovation EcosystemSouth Korea strengthens targeted sequencing capabilities through investments in biotechnology, precision healthcare, and genomic research. Local organizations increasingly deploy high-throughput sequencing platforms to accelerate clinical applications and biomedical discoveries.
United States 🇺🇸
Precision Genomics ExpansionThe U.S. continues expanding targeted sequencing and resequencing across precision medicine, oncology, and clinical diagnostics. Healthcare providers and research institutions prioritize scalable sequencing platforms that improve genomic interpretation and support personalized treatment decisions.
Segment Leadership and Growth Trends
Targeted Sequencing and Resequencing Market Share (%), Technology, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSequencing held the strongest position in the targeted sequencing and resequencing market in 2025, accounting for a 68.68% share. Its dominance is sustained by its central role in generating primary genomic data for research, assay development, and mutation detection workflows, making it the default technology choice across a wide range of targeted applications. In practice, organizations in the targeted sequencing and resequencing market rely on sequencing when establishing baseline genetic profiles and conducting first-pass analyses, which keeps demand concentrated in this segment.
Re-sequencing is emerging as the fastest-growing technology segment in the targeted sequencing and resequencing market because it aligns well with the increasing need to revisit known genomic regions with greater precision and efficiency. Its momentum is aided by practical use cases where users are validating previously identified variants, refining earlier findings, or monitoring specific targets over time rather than repeating broader discovery-oriented workflows. Compared with initial sequencing, re-sequencing gains traction where cost control, faster turnaround, and focused analysis are becoming more important in routine and follow-up applications.
End-use Segment Analysis: Academic Research (Largest Segment) vs Hospitals & Clinics (Fastest-Growing Segment)
Academic research represented the largest end-use segment in the targeted sequencing and resequencing market in 2025, with a 52.86% share. This leadership reflects the continued concentration of sequencing-based projects in universities, research institutes, and genomics-focused laboratories, where targeted analysis is widely used to study disease mechanisms, identify variants, and support translational science. The targeted sequencing and resequencing market remains closely tied to academic research activity because these institutions sustain a high volume of exploratory and hypothesis-driven studies that regularly depend on targeted genomic workflows.
Hospitals & clinics are the fastest-growing end-use segment in the targeted sequencing and resequencing market as genomic testing moves closer to routine patient management. Growth is being driven by the practical adoption of targeted panels and focused resequencing approaches in clinical environments that require actionable results, shorter reporting windows, and clearer alignment with diagnosis or treatment decisions. Relative to academic settings, hospitals & clinics are gaining momentum because the value of targeted genomic information is becoming more directly embedded in care pathways rather than remaining concentrated in research-led use cases.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Sequencing, Re-sequencing | Sequencing | Re-sequencing |
| End-use | Hospitals & Clinics, Academic Research, Others | Academic Research | Hospitals & Clinics |
| Type | DNA-based Targeted Sequencing, RNA-based Targeted Sequencing | DNA-based Targeted Sequencing | RNA-based Targeted Sequencing |
| Application | Clinical Application, Plant and Animal Sciences, Drug Development, Others | Clinical Application | Drug Development |
Competitive Landscape and Market Positioning
1. Illumina Inc. (United States)
2. Agilent Technologies Inc. (United States)
3. F. Hoffmann-La Roche Ltd. (Switzerland)
4. Thermo Fisher Scientific Inc. (United States)
5. Bio-Rad Laboratories Inc. (United States)
6. Oxford Nanopore Technologies plc (United Kingdom)
7. Pacific Biosciences of California Inc. (United States)
8. QIAGEN N.V. (Germany)
9. BGI Genomics Co. Ltd. (China)
10. PerkinElmer Inc. (United States)
Continuous innovation in genomic analysis is driving the targeted sequencing and resequencing market, with advanced sequencing technologies and AI-assisted data interpretation improving analytical precision. Strong research investments are expanding applications in clinical diagnostics, oncology, and genetic research.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| QIAGEN N.V. | Mar-22 | QIAGEN N.V. collaborated with NHS England and NHS Improvement to deploy its Human Gene Mutation Database for interpretation of next-generation sequencing data in inherited diseases. The initiative supported improved clinical interpretation workflows and reinforced QIAGEN’s role in enabling genomic diagnostics adoption within healthcare systems. |
| Illumina, Inc. | Sep-21 | Illumina, Inc. announced expansion plans for its genomics operations in Latin America through the establishment of local entities in Colombia and Mexico. The initiative was aimed at strengthening regional customer engagement and expanding access to sequencing technologies across emerging healthcare and research markets. |
| Illumina, Inc. | Apr-25 | Illumina, Inc. entered a strategic partnership with Tempus AI to accelerate adoption of AI-driven next-generation sequencing tests. The collaboration focused on integrating computational capabilities with sequencing workflows to improve diagnostic development efficiency and support broader clinical utilization of genomic testing platforms. |
| GeneDx | Apr-25 | GeneDx acquired Fabric Genomics to scale decentralized AI-powered genomic testing capabilities. The acquisition strengthened GeneDx’s precision diagnostics infrastructure and expanded its ability to deliver distributed sequencing and interpretation solutions across clinical genomics applications. |
| Illumina, Inc. | Jun-25 | Illumina, Inc. acquired SomaLogic for up to USD 425 million to expand its presence into proteomics through the SomaScan platform. The transaction broadened Illumina’s multi-omics capabilities, enabling integration of protein-level data with sequencing-based genomic analysis for enhanced biomarker discovery applications. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Targeted Sequencing and Resequencing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Targeted Sequencing and Resequencing Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the targeted sequencing and resequencing market?
What are the growth projections for the targeted sequencing and resequencing industry?
How is the shift toward precision oncology influencing adoption of targeted sequencing in clinical decision-making workflows?
What is driving the increasing relevance of re-sequencing compared with traditional sequencing approaches?
Why is Sequencing the largest technology segment in the targeted sequencing and resequencing market?
Why are Hospitals & Clinics the fastest-growing end-use segment in the targeted sequencing and resequencing market?
What factors support North America's leadership in the targeted sequencing and resequencing market?
Why is Asia Pacific emerging as the fastest-growing regional market?
Who are the leading players in the targeted sequencing and resequencing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization